



500 Linden Oaks
Rochester, New York 14625

FOR IMMEDIATE RELEASE

CONTACT: Investor Relations Contact:
BPC Financial Marketing
John Baldissera
(800)368.1217

Company Contact:
Molly Henderson
Chief Financial Officer
500 Linden Oaks
Rochester, New York 14625
(585)249.6231

THREE ONCOLOGY PRESENTATIONS BY VIRTUALSCOPICS LEAD SCIENTIST AT INTERNATIONAL MRI MEETING

ROCHESTER, N.Y. – May 6, 2008 – VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of advanced medical imaging for clinical trials, announced today that its Chief Scientific Officer, Dr. Edward Ashton, Ph.D. will have two speaking engagements and co-author an abstract at the International Society for Magnetic Resonance Imaging in Medicine (ISMRM) conference in Toronto, Canada. Dr. Ashton's presentations on May 7 and 8, 2008 will focus on the company's work in dynamic contrast enhanced MRI, an advanced medical image analysis technique that measures blood flow and permeability and enables the early detection of a drug's effectiveness in treating cancer and other diseases.

“Our proprietary analysis techniques surrounding the measuring of blood flow within a tumor continue to demonstrate great value to the industry,” stated Dr. Ashton. He further added, “Because of the improved specificity and sensitivity of our tools we were able to determine that our method, compared to three other methods, was the only one that detected the treatment effect of our customer's compound. Our presentations at this year's ISMRM conference will be made in conjunction with leaders in the pharmaceutical industry to highlight the impacts our analysis tools have made in providing them with quicker and more reliable information to evaluate the efficacy of their drugs.”

Dr. Ashton will also present data related to treating naturally occurring solid tumors in canines. VirtualScopics image analysis tools were used to discover important information about the way tumors respond to radiation therapy. This may ultimately impact the treatment planning of patients following radiation therapy as this research can now be carried over into human studies.

In both human and animal health studies VirtualScopics is able to provide drug makers with more information sooner enabling them to make earlier decisions on either suspending ineffective drug trials, or moving effective drugs forward, in the expensive clinical trial process, saving drug makers significant time and money.

About VirtualScopics, Inc.

VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development. VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images. In combination with VirtualScopics'

industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster. For more information about VirtualScopics, visit www.virtualscopics.com.

####

Forward-Looking Statements

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission.